MSN Labs launches Posaconazole to treat black fungus
Posaconazole is a triazole antifungal agent indicated for treating mucormycosis detected among patients who are recovering from Covid-19.
Hyderabad: Hyderabad-based MSN Laboratories launched Posaconazole, under the brand PosaOne as 100 mg delayed release tablets and 300 mg injections.
Posaconazole is a triazole antifungal agent indicated for treating mucormycosis patients. Each tablet is priced at Rs 600, while the injection is priced at Rs 8,500 per unit, the company said.
Many patients recovering from Covid 19 have been detected with a fungal infection known as mucormycosis or black fungus.
As an outcome of MSN’s competence in research and manufacturing of anti-fungal infection drugs, it is now targeting to pro-actively reach patients across India by ensuring the access of PosaOne, through its distribution network and field force.
MSN has developed the active pharmaceutical ingredient and the formulation of PosaOne in its in-house R&D and manufacturing units. The drug is approved by the Drug Controller General of India (DGCI).
As part of the Covid treatment range, MSN has already launched Favilow (Favipiravir) in the strengths of 200mg, 400mg and 800mg, Oselow (Oseltamivir) as 75 mg capsules and also licensed Baridoz (Baricitinib) recently with Eli Lilly.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .
